Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II azacitidine study in corticosteroid-refractory chronic graft-versus-host disease
2014-005659-19Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Mar 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in chronic graft-versus-host disease (cGVHD) and Acute Graft-Versus-Host Disease (aGvHD), sponsored by University of Birmingham. Primary endpoint: Best overall response within 6 months. Status: unknown.
02
Drugs
azacitidine
03
Conditions
chronic graft-versus-host disease (cGVHD)Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on 2014-005659-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005659-19.